OmniAb

Goldman Sachs highlights biotech stocks as under-the-radar opportunities due to their sensitivity to interest rate changes and significant upside potential. The sector benefits from improved fundamentals, positive clinical outcomes, and a favorable regulatory environment. Small and emerging biotech firms are leading innovation, with increased M&A activity expected. OmniAb, Inc. (OABI) is noted for its innovative antibody discovery technologies and ranks 12th among the best biotech penny stocks to invest in now.

Tharimmune plans to initiate a Phase 2 study of TH104 for moderate-to-severe pruritus in PBC patients in 2025, following positive Phase 1 results and regulatory feedback. The company achieved milestones in manufacturing, clinical trials, and regulatory progress in 2024, and expanded its Board of Directors with the appointment of Sanam Parikh.

Dr. Urban A. Kiernan founded iMetabolic Biopharma Corporation (iMBP) in 2017, driven by personal loss and a desire to address disease root causes. iMBP focuses on precision medicine using its proprietary iPlatform, combining biotechnology and AI to develop personalized therapies for diseases like cardiovascular conditions, obesity-related diseases, and neurodegenerative disorders. Kiernan aims to transform healthcare by offering more effective treatments and healthier lives.

Tharimmune, Inc. raises $2.02 million in a private placement, issuing 961,446 shares at $2.10 each with warrants. Proceeds will fund TH104 development for chronic pruritus in PBC and general working capital. Gravitas Capital and SDS Capital Group led the financing.

Tharimmune, Inc. announces CEO Randy Milby's participation in the 2024 Spartan Capital Investor Conference on Nov 4 in NYC and CMA Nir Barak's poster presentation on TH104 at AASLD's The Liver Meeting® 2024 on Nov 18 in San Diego.

Tharimmune, Inc. received positive feedback from the EMA on TH104, its lead candidate for pruritus in PBC, with guidance on Phase 2 and 3 trials. The EMA endorsed the strategy and found the Phase 2 study design acceptable, providing general guidance for Phase 3. Tharimmune plans to initiate a Phase 2 trial in the coming months, expecting topline data in 2025.

Tharimmune to acquire Intract, forming a transformative oral biologics company. Intract shareholders will own 49% of the combined entity, expected to close in 1Q25. The merger aims to drive pipeline growth and strengthen Tharimmune's position in the biologics market.